Branch retinal vein occlusion (BRVO) is an obstruction of the major retinal vein that occurs most commonly at an arteriovenous crossing. It occurs due to thrombosis of a branch of the central retinal vein resulting in retinal hemorrhages, cotton wool spots, and varying amounts of retinal nonperfusion in the area drained by the occluded vessel. Macular edema (ME) is the most common cause of vision loss, others being macular ischemia and sequelae of neovascularization such as vitreous hemorrhage, neovascular glaucoma, and tractional retinal detachment.

Vascular endothelial growth factor (VEGF) is considered to play an important role in the pathogenesis of ME with BRVO.\[[@ref1]\] Noma *et al*. demonstrated that aqueous levels of VEGF and IL-6 were significantly elevated in patients of BRVO\[[@ref2]\] compared to controls. A high level of VEGF produced by the ischemic retina exacerbates retinal vascular leakage and neovascularization. Therefore, anti-VEGF drugs play a critical role in the treatment of ME with BRVO. Campochiaro *et al*. demonstrated that intraocular injections of 0.3 mg or 0.5 mg Ranibizumab provided rapid, effective treatment for macular edema following BRVO.\[[@ref3][@ref4]\]

Currently, anti-VEGF is the gold standard treatment for the management of macular edema in vein occlusions, especially BRVO. However, due to their limited half-life,\[[@ref5][@ref6]\] single injection of anti-VEGF agents provide temporary relief with high chances of recurrence of macular edema and need for repeated injections. This adds on to the economic burden of treatment, increased number of hospital visits apart from the risk of repeated intravitreal injections such as endophthalmitis and retinal detachment. Thus, there is a need for a treatment option that may act as an adjuvant to the current gold standard and help in decreasing the number of injections required.

Ultra-widefield (UWF) imaging (Optos Tx200, Optos Inc.) is capable of capturing a 200^0^ field allowing for a simultaneous view of the posterior pole, mid-periphery, and periphery.\[[@ref7]\] In a study, Wessel *et al*.\[[@ref8]\] demonstrated that UWF angiography detected 3.9 times more areas of capillary nonperfusion (CNP) than conventional angiography in patients with diabetic retinopathy. The peripheral CNP areas in the setting of BRVO can act as a continuous source of VEGF and maybe the potential area of interest as their selective ablation by laser photocoagulation may reduce the continuous VEGF production and thus reduce the number of treatments with anti-VEGF agents. This concept of targeted retinal photocoagulation (TRP) has shown its utilization in proliferative diabetic retinopathy.\[[@ref9]\] We thus conducted this randomized clinical trial to determine whether targeted laser photocoagulation promotes resolution of macular edema, reduces the need for VEGF antagonists, and improves visual outcomes in patients with BRVO.

Methods {#sec1-2}
=======

This is a prospective, randomized interventional study conducted at a tertiary eye care center in North India. 33 eyes of 32 patients with BRVO presenting to the retina clinic were enrolled from May 2015 to July 2016. The study was conducted in accordance with the Declarations of Helsinki and informed consent was obtained from all the enrolled participants. Ethical clearance was obtained from the Institute Ethics Committee. The trial was registered with CTRI (CTRI/2018/03/012383).

Patients with decreased visual acuity secondary to BRVO with macular edema were eligible for the study if they had a visual acuity between 20/400 and 20/63 and macular edema with a central subfoveal thickness (CST) greater than 300 μm presenting within 3 months of disease onset. Patients who were pregnant, had uncontrolled hypertension or diabetes, had macular ischemia, had sensitivity to sodium fluorescein, had received prior anti-VEGF injection or scatter laser photocoagulation, or had any other additional ocular diseases that could irreversibly compromise the visual acuity of the study eye were excluded from the study.

Patients underwent a comprehensive ophthalmologic examination that included visual acuity assessment using Early Treatment Diabetic Retinopathy Study (ETDRS) protocol (ETDRS Illuminated Cabinet, Netherlands), intraocular pressure using Goldmann applanation tonometer, slit-lamp biomicroscopy using 90 D, swept-source optical coherence tomography (SS-OCT, DRI Triton, Topcon, Tokyo, Japan), Pelli Robson contrast sensitivity (Pelli-Robson Contrast Sensitivity Chart, Haag-Streit, UK), Humphrey visual fields (30-2 Swedish Interactive Threshold Algorithm; Humphrey Field Analyser Model 750*i*, Carl Zeiss Meditec Inc., Dublin, California), and UWF fluorescein angiography (UWFFA) using Optos C200MA (Optos Plc, Dunfermline, Scotland). The visual acuity assessors and OCT graders were not masked.

The patients were randomized to 0.5 mg Ranibizumab only (RBZ group) or Ranibizumab with UWFFA (Optos, Optos Inc)-guided TRP (PASCAL laser, RBZ + TRP group). The patients were randomized using sealed envelopes containing allocation to either group. Patients in both groups received three loading injections at monthly intervals. All patients of the RBZ + TRP group additionally underwent UWFFA-guided PASCAL-targeted photocoagulation at 1 week after the first injection. After the first three injections, the patients in both the groups were treated with 0.5 mg Ranibizumab according to pro re nata regimen if visual acuity was \<20/40 or central subfoveal thickness \>300 μm. Patients in both the groups were followed-up for a minimum of 9 months.

UWFFA was done at baseline and 9 months for every patient \[[Fig. 1a](#F1){ref-type="fig"}\]. A single trained optometrist performed it, and areas of CNP were delineated. CST was assessed by SS-OCT at each follow-up visit at monthly intervals. In the RBZ + TRP group, TRP of CNP areas was carried out by a single experienced retina specialist on day 7 of the first injection. TRP was carried out using Pattern Scan Laser (PASCAL, Topcon Medical Laser Systems, Santa Clara, CA, USA). Topical 0.5% Proparacaine was used to anesthetize the eyes before the procedure. Topical 0.5% Moxifloxacin was instilled at the end of the procedure. Capillary nonperfusion areas were selectively lasered using PASCAL 4\*4 array with 20 ms pulse duration using QuadrAspheric lens (Volk Optical Inc., OH, USA) with a magnification factor of 0.51 and retinal spot size of 200 μm. Laser burns were applied to the CNP areas and at the junction of ischemic and nonischemic areas, extending anteriorly up to ora serrata \[[Fig. 1b](#F1){ref-type="fig"}\]. The laser spots were placed 1 burn width apart, and the end point of the laser was taken to be moderate gray burns.

![Patient having BRVO with macular edema in RBZ + TRP group. (a) Ultra-widefield angiogram of a patient with inferotemporal BRVO showing peripheral CNP areas. (b) Ultra-widefield angiogram of the same patient following targeted retinal photocoagulation](IJO-67-1105-g001){#F1}

The primary outcome parameter was the mean change in best-corrected visual acuity (BCVA) from the baseline at 9 months. The secondary outcome parameters were the mean decrease in central subfoveal thickness as measured on serial SS-OCT scans, number of injections required, change in mean deviation (HVF 30-2 SITA standard), and Pelli Robson contrast sensitivity.

Statistical analysis was performed using Strata (Version 12.1). For pre- and postinjection analysis, paired *t*-test was used to evaluate the changes in CST. For nonparametric data, that is, visual acuity, contrast sensitivity, and mean deviation on visual fields, Wilcoxon signed-rank test was used. For intergroup analysis, two-sample *t*-test was used for parametric data and Mann--Whitney test was done for nonparametric data. *P* values less than 0.05 were considered statistically significant.

Results {#sec1-3}
=======

A total of 33 eyes were enrolled: 17 were randomized to the RBZ group and 16 to the RBZ + TRP group. Both the groups were comparable in demography and baseline characteristics \[[Table 1](#T1){ref-type="table"}\]. In our study, 64% of cases had superotemporal BRVO and 36% had inferotemporal BRVO. Significant improvement in visual acuity was noted in both the groups (*P* \< 0.001 in each group). The average gain in ETDRS letters in RBZ group was 25.7 ± 8.2 (95% CI: 21.5--29.9) vs. 23.38 ± 7.6 (95% CI: 19.3--27.4) in the RBZ + TRP group. Both the groups individually had significant improvement in BCVA. However, the intergroup analysis revealed that the difference in gain in BCVA was not significant. (*P* = 0.93) \[[Fig. 2](#F2){ref-type="fig"}\]. No patients had a loss of more than five letters in our study. Among the 33 study patients, 26 patients gained more than 15 letters. Similarly, a significant decrease in CST was noted in both the groups (*P* \< 0.001 in each group). The mean change in CST in RBZ group was 379.12 ± 242.7 μm (95% CI: 254.3--503.9) vs. 253.75 μm ± 137.9 (95% CI: 180.3--327.3) in the RBZ + TRP group; however, the difference between the two groups was not statistically significant. (*P* = 0.06) \[[Fig. 3](#F3){ref-type="fig"}\]

###### 

Demography and baseline characteristics of patients in both the groups (RBZ and RBZ + TRP)

  Parameter                        RBZ group       RBZ + TRP group   *P*
  -------------------------------- --------------- ----------------- ------
  Age (years)                      55.88±9.21      54.25±9.56        0.86
  Males                            47%             37%               0.57
  Females                          53%             63%               0.57
  Phakic                           88.24%          75%               0.32
  Pseudophakic                     11.76%          25%               0.32
  Diabetes                         23.53%          18.75%            0.73
  Hypertension                     58.82%          87.5%             0.06
  Coronary artery disease          5.88%           18.75%            0.33
  LogMAR VA (Snellen equivalent)   0.93 (20/170)   0.88 (20/150)     0.59
  CST (μm)                         631.88          496.69            0.69
  IOP (mmHg)                       15.41±2.52      15.63 3.28        0.83

![Change in logMAR visual acuity in RBZ group and RBZ + TRP group](IJO-67-1105-g002){#F2}

![Change in central subfoveal thickness in RBZ group and RBZ + TRP group](IJO-67-1105-g003){#F3}

The number of injections required ranged from 3 to 8 (mean = 5.76 ± 1.3) in RBZ group and from 3 to 6 (mean = 4.06 ± 0.99) in RBZ + TRP group. This difference was statistically significant (*P* \< 0.001, Mann--Whitney test). The intraocular pressure (IOP) in both groups showed no significant change from baseline IOP (*P* = 0.64 and *P* = 0.177 respectively).

The baseline mean contrast sensitivity was 1.2 ± 0.25 in the RBZ group and 1.22 ± 0.27 in the RBZ + TRP group. The contrast sensitivity at 9 months was 1.36 ± 0.20 and 1.4 ± 0.22 in the RBZ and RBZ + TRP groups, respectively. Both the groups had significant improvement in contrast sensitivity (*P* \< 0.001 in each group); however, the difference between the two groups was not statistically significant (*P* = 0.62). Patients in both groups demonstrated significant improvement in mean deviation on visual fields from baseline (*P* = 0.008 and *P* = 0.004, respectively). None of the patients showed difficulty in fixation during visual field analysis despite macular edema. None of the patients showed disease progression or complications related to laser photocoagulation or intravitreal injection during the study period.

Discussion {#sec1-4}
==========

VEGF is a potent angiogenic factor produced by Muller cells of the hypoxic retina\[[@ref10]\] due to vascular occlusion-related retinal ischemia leading to increased vascular permeability, leakage, and neovascularization. These factors contribute to macular edema, which is the main cause of visual morbidity in patients with venous occlusions. Anti-VEGF agents are thus, the mainstay for treatment of macular edema following BRVO. However, multiple injections are required to maintain the effect. The need for repeated injections can be explained by the short vitreous half-life of 7.19 days of intravitreal Ranibizumab (Krohne *et al*.).\[[@ref6]\] Studies done by Prasad *et al*. have demonstrated a positive correlation with untreated nonperfusion anterior to the equator with macular edema and neovascularization in cases of RVO.\[[@ref11]\] Thus, untreated areas of retinal nonperfusion may be the source of continuous production of VEGF leading to recurrence of macular edema after intravitreal anti-VEGF injection. Furthermore, the size of retinal nonperfusion is correlated with the severity of macular edema.\[[@ref12][@ref13]\] Thus, we conceptualized this study with the hypothesis that treatment of these target areas of nonperfusion can reduce the production of VEGF and thereby decrease the number of anti-VEGF injections required.

In our study, both groups showed similar improvement in terms of visual acuity (VA) and CST. In addition, contrast sensitivity and visual field sensitivity improved significantly in both groups. We hypothesize that anti-VEGF injections by decreasing the macular edema improves the macular function and thereby increases the contrast sensitivity. As also suggested by Muqit *et al*.,\[[@ref9]\] the improved visual field sensitivity after TRP could be attributed to a reduction in retinal ischemia. The number of injections required was significantly reduced in the group where additional TRP was performed.

Similar results were demonstrated by Tomomatsu *et al*. suggesting that TRP of nonperfusion areas reduced the amount of ME recurrence following intravitreal Bevacizumab compared to Bevacizumab alone.\[[@ref14]\] However, our study differed in the protocol of treatment, which involved monthly injections for the first 3 months along with laser after the first injection. We used UWFFA that helps to document a larger area of peripheral CNP\[[@ref8]\] that could be targeted with laser. The anti-VEGF used in our study was Ranibizumab, which is approved by the FDA for the treatment of macular edema in BRVO. The RELATE trial,\[[@ref15]\] on contrary, suggested that scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion. The study differed significantly from our study in the treatment protocol. The laser photocoagulation in the RELATE trial was performed after 6 months of anti-VEGF treatment, while it was performed in our study after the first injection itself. This could affect the number of injections as the greatest number of treatments for macular edema in BRVO are usually done in the first 6 months itself. The RELATE trial did not recruit treatment naïve eyes. Recently, the WAVE study with a sample size of 30 patients on 12 months follow-up demonstrated no added benefit of TRP on treatment burden or visual outcomes in ischemic RVO.\[[@ref16]\] However, a major difference from our study was the inclusion criteria that included patients with CRVO or BRVO demonstrating an incomplete response to previous anti-VEGF treatments. Patients with poor response to anti-VEGF for resolution of macular edema may be attributed to additional inflammatory factors such as IL-6. This may attribute to the difference in WAVE study from our study as we included only treatment-naive patients with BRVO.

The limitations of our study were a small sample size and a relatively small follow-up period. The area of CNP was not quantified, and there may be a difference in the amount of CNP in the two groups at baseline. In addition, the use of other modalities that can assess the peripheral field to study the development of peripheral scotoma due to TRP will be beneficial. Longer follow-up studies with larger sample size are required to assess the long-term benefit of the added laser to Ranibizumab-treated patients of BRVO.

Conclusion {#sec1-5}
==========

To conclude, targeted laser photocoagulation of peripheral CNP areas in BRVO with macular edema may decrease the need for repeated anti-VEGF injections and injection-related complications while maintaining similar benefits in visual acuity, contrast sensitivity, and visual fields, especially in treatment-naive patients. This may bring down the healthcare cost related to management of venous occlusions.
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